VolitionRx Limited filings document an operating epigenetics diagnostics company with public-company disclosures centered on Nu.Q® assays, capital structure and exchange compliance. Recent 8-K reports and proxy materials cover shareholder votes on common-stock issuance capacity and reverse-stock-split authority, the effectiveness of a one-for-twenty reverse split, and amendments to the company’s certificate of incorporation.
The filing record also includes material-event reports on NYSE American continued-listing standards, annual financial-result updates, unregistered sales of equity securities, convertible-note share settlements, private placements and warrants. These documents describe governance approvals, security-holder rights, financing mechanics, listing-compliance matters and operating updates for Volition’s diagnostics and monitoring business.
Transaction summary: Ann-Louise Batchelor, Group Chief Marketing Officer, filed a Form 4 for VolitionRx Ltd (VNRX) reporting activity dated 08/01/2025.
Details: The filing states 18,341 restricted stock units were settled in lieu of cash compensation and that 8,620 shares were retained by VolitionRx for cancellation to satisfy the reporting person’s tax withholding obligations. The filing explicitly states no shares were sold. Following the reported transaction, Batchelor beneficially owns 132,486 shares directly and 29,406 shares indirectly (by spouse). The table shows a price of $0.64. Form signed 08/05/2025.
VolitionRx Ltd. (VNRX) – Form 4 filing
Chief Commercial Officer Gael Forterre reported a single Code F transaction on 1 Aug 2025, reflecting shares surrendered to the company to cover taxes upon settlement of 6,690 restricted stock units received in lieu of cash compensation. 2,766 common shares were withheld at an implied price of $0.64 and therefore cancelled; no open-market sale occurred.
Following the withholding, Forterre’s holdings stand at 156,700 directly-owned shares. He also reports 5,000 shares held indirectly by his spouse and 32,500 shares managed through Armorica Partners, LLC, over which he exercises voting and dispositive control. The filing represents routine administrative tax withholding and does not signal a change in insider ownership intent or corporate outlook.